

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on JAN 29 2002

William J. Winter 36,060
Name of Attorney Registration No.
William J. Winter
Signature of Attorney

P&G Case 8765

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
E. D. SMITH, III ET AL. : Confirmation No.
Serial No. 10/033,098 : Group Art Unit
Filed November 11, 2001 : Examiner

For PERSONAL CARE COMPOSITIONS CONTAINING A WATER DISINTEGRATABLE
POLYMERIC FOAM

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☒ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☐ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s ____, were submitted and considered in parent application U.S. Patent Application Serial No. ____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s ____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s ____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.



Additional information is attached.

Respectfully submitted,

By 
William J. Winter
Attorney for Applicants
Registration No. 36,060
(513) 626-2980

Jan 29, 2002


Customer No. 27740

COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
8766	10/035,380	Smith et al.	11/01/2001

Please type a plus sign (+) inside this box → [+]



PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(use as many sheets as necessary)</p> <p>SHEET 1 of 2</p>	COMPLETE IF KNOWN	
	Application Number	10/033,098
	Confirmation Number	
	Filing Date	11/01/2001
	First Named Inventor	Wayne Ellis Eccard
	Group Art Unit	
	Examiner Name	
Attorney Docket Number	8765	


U. S. PATENT DOCUMENTS

	01	3,695,989		Albert	10/03/1972	
	02	3,962,155		Usamoto et al.	06/08/1976	
	03	4,642,903		Davies	02/17/1987	
	04	4,692,473		Wright et al.	09/08/1987	
	05	4,874,538		Dawson et al.	10/17/1989	
	06	5,062,986		Fujita et al.	11/05/1991	
	07	5,089,535	A	Malwitz et al.	02/18/1992	
	08	5,147,344	A	Sachau et al.	09/15/1992	
	09	5,207,837	A	Honeycutt	05/04/1993	
	10	5,405,616	A	Wunderlich et al.	04/11/1995	
	11	5,456,745	A	Roreger et al.	10/10/1995	
	12	5,543,439	A	McDermott et al.	08/06/1996	
	13	5,700,553	A	Cohen et al.	12/23/1997	
	14	5,868,991	A	Faass et al.	02/09/1999	
	15	6,106,849	A	Malkan et al.	08/22/2000	
	16	6,117,438	A	Topolkaraev et al.	09/12/2000	
	17	6,177,391	B1	Zafar	01/23/2001	
	18	6,187,728	B1	McManus	02/13/2001	
	19	6,231,957	B1	Zerbe et al.	05/15/2001	
	20	6,251,954	B1	Roulier et al.	06/26/2001	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	21	EP 0 533 393 A	Unilever	03/24/1993		
	22	EP 0 747 720 A1	General Electric	12/11/1996		
	23	CN 1134450 A	Zhou X	10/30/1996		Abstract
	24	CN 1,138,091 A	Cao Desheng	12/18/1996		X
	25	CN 1,268,558 A	Xiaolin Yi	10/04/2000		X
	26	DE 19947684 A1	Henkel KGAA	04/12/2001		Abstract
	27	GB 2 297 975 A	Procter & Gamble	08/21/1996		Abstract
	28	JP Sho 55-165998	Sumitomo Bakelite	12/24/1980		X
	29	JP 62-072,609	Sunstar Inc.	04/03/1987		Claims only
	30	JP 6 2072610 A	Sunstar KK	04/03/1987		Abstract
	31	JP 6 2238209 A	Nippon Biochem	10/19/1987		Abstract
	32	JP 62-294,604	Mitsui Toatso Chem	12/22/1987		X
	33	JP 01131109 A	Lion Corp	05/24/1989		Abstract
	34	JP 02-279800	Kai Ichi Kogyo	11/15/1990		Abstract
	35	JP 04103521 A	Tsumura & Co.	04/06/1992		Abstract
	36	JP 01243818 A	Fuji Capsule KK	08/31/1992		Abstract
	37	JP 05124954 A	Mitsubishi Kasei	05/21/1993		Abstract
EXAMINER				DATE CONSIDERED		

Please type a plus sign (+) inside this box → [+]



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Substitute for form 1449A/PTO

PTO/SB08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2

COMPLETE IF KNOWN

Application Number	10/033,098
Confirmation Number	
Filing Date	11/01/2001
First Named Inventor	Wayne Ellis Eccard
Group Art Unit	
Examiner Name	
Attorney Docket Number	8765

FOREIGN PATENT DOCUMENTS - continued

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	38	JP 07-330580	Unitika Ltd.	12/19/1995		Abstract
	39	JP 08-03848	Kuraray Co. Ltd.	01/09/1996		Claims only
	40	JP 09104617	Kao Corp	04/22/1997		Abstract
	41	JP 09-216809	Kao KK Labs	08/19/1997		Claims only
	42	JP 09327508	Kotec KK	12/22/1997		Abstract
	43	JP 11021229	Kyoto Yakuhn	01/26/1999		Abstract
	44	JP 11138700	Nippon Syn Chem	05/25/1999		Abstract
	45	JP 11049635	Nitto Denko Corp	02/23/1999		Abstract
	46	JP 11140758	Nippon Syn Chem	05/25/1999		Abstract
	47	JP 11140759	Nippon Syn Chem	05/25/1999		Abstract
	48	JP 11140760	Nippon Syn Chem	05/25/1999		Abstract
	49	JP 11140761	Nippon Syn Chem	05/25/1999		Abstract
	50	JP 11104762	Nippon Syn Chem	05/25/1999		Abstract
	51	JP 11140763	Nippon Syn Chem	05/25/1999		Abstract
	52	JP 11140765	Nippon Syn Chem	05/25/1999		Abstract
	53	JP 11140776	Nippon Syn Chem.	05/25/1999		Abstract
	54	JP 200019171	Kao Corp	04/25/2000		Abstract
	55	WO 96/25144	Procter & Gamble	08/22/1996		
	56	WO 97/35542	Procter & Gamble	10/02/1997		
	57	WO 01/01950	Procter & Gamble	01/11/2001		
	58	WO 01/25323	Procter & Gamble	04/12/2001		
	59	WO 01/24779	Procter & Gamble	04/12/2001		
	60	WO 01/24990	Procter & Gamble	04/12/2001		
	61	WO 01/25322	Procter & Gamble	04/12/2001		
	62	WO 01/25390	Procter & Gamble	04/12/2001		
	63	WO 01/25393	Procter & Gamble	04/12/2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.